Cerespir

CereSpir is a private pharmaceutical company located in New York, New York, USA, founded by Dr. Daniel G. Chain. In November 2013, the company acquired full rights to CSP-1103 and became the official sponsor of the IND in March 2014. CSP-1103 is a novel, first-in-class small molecule microglial modulator. In a Phase 2 trial involving patients with mild cognitive impairment (MCI), CSP-1103 was well-tolerated and appeared to both reduce brain inflammation and sustain cognitive function. MCI causes a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. According to the latest report from the Alzheimer's Association, most patients diagnosed with MCI progress to AD, which currently affects over 5 million Americans, 7 million Europeans, and approximately 44 million people worldwide.